Clinical trial
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With…
NCT00301366 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00301366 |
|---|---|
| Title | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency |
| Official title | Multi-center, Open-label Trial to Evaluate the Safety and Tolerability of Alpha-1 MP in Subjects With Alpha-1-antitrypsin (AAT) Deficiency |
| Acronym | STAMP |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alpha 1-Antitrypsin Deficiency |
| Intervention type | Drug |
| Interventions | alpha-1 proteinase inhibitor (human) |
| Enrollment | 38 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Mar 10, 2006 |
| Last update posted | Aug 19, 2014 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: